Maharashtra FDA Cancels Cipla Pharma’s Pune Unit Licence Over Reactin Plus Lapses
Source ↗
👁 0
💬 0
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s carrying and forwarding (C&F) facility at Wadki in Pune, effective August 27, 2026, following inspections that found multiple alleged regulatory violations involving Reactin Plus Tablets. The prescription medicine, classified as a Schedule H drug, was found carrying the unauthorised claim “analgesic and antipyretic” on its packaging, along with promotional materia
Comments (0)